The Report “PharmaPoint: Prophylactic Hepatitis B Virus
Vaccines – 5EU Drug Forecast and Market Analysis to 2022″ by GlobalData is now
available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com
with “PharmaPoint: Prophylactic Hepatitis B Virus Vaccines – 5EU Drug Forecast
and Market Analysis to 2022″ in subject line and your contact details to
purchase this report or get your questions answered.
Hepatitis B, which is caused by the hepatitis
B virus (HBV), is characterized by acute or chronic inflammation of the
liver. Researchers and healthcare experts have estimated that roughly two
billion people are infected with HBV worldwide, with roughly 600,000 people
dying each year from HBV-related liver diseases. While the arrival of
recombinant HBsAg vaccines has greatly reduced disease burden over the past two
decades, questions surrounding vaccine uptake and effectiveness in adults,
particularly in niche patient populations, still remain. It expects that the
growing popularity of pediatric combination vaccines, along with the arrival of
vaccines that achieve higher seroconversion rates in high-risk adults, will
serve to stimulate growth in the marketplace over the forecast period.
Country-specific immunization recommendations and policy implementation will be
an essential metric for determining future vaccine uptake in the 7MM (US,
France, Germany, Italy, Spain, UK, and Japan) and Canada.
It’s primary and secondary research has revealed that the
reimbursement of Infanrix Hexa, which began in 2008, has helped France’s
routine HBV immunization program recover from safety concerns (CTV, 2012; Denis
et al., 2013). The adult HBV vaccine market in Germany is also expected to grow
during the forecast period, led by the arrival of Dynavax Technologies’
Heplisav in the second half of 2018. GSK dominated Italy’s HBV vaccine market
in 2012. Sanofi Pasteur MSD’s monovalent vaccine, HBVaxPro, accounted for the
remaining market share. More specifically, It expects the arrival of Sanofi
Pasteur MSD’s Hexyon to be the principal driver of Spain’s market growth, as it
should compete with Infanrix Hexa for market share in the routine immunization
program. It’s primary research has revealed that challenging barriers to
growth, such as poor funding mechanisms due to government spending concerns,
inadequate physician education, and low patient awareness, will limit adult
vaccine uptake and growth of this segment of the market in the UK.
Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=164947
.
Scope
·
Overview
of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive
landscape.
·
Detailed
information on the key drugs in 5EU including product description, safety and
efficacy profiles as well as a SWOT analysis.
·
Sales
forecast for the top drugs in 5EU from 2012-2022.
·
Analysis
of the impact of key events as well the drivers and restraints affecting the 5EU
Hepatitis B disease market.
Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-prophylactic-hepatitis-b-virus-vaccines-5eu-drug-forecast-and-market-analysis-to-2022-market-report.html
. Read more on “PharmaPoint: Prophylactic Hepatitis B Virus Vaccines – 5EU
Drug Forecast and Market Analysis to 2022” report below.
Reasons to buy
·
Understand
and capitalize by identifying products that are most likely to ensure a robust
return
·
Stay
ahead of the competition by understanding the changing competitive landscape
for Hepatitis B disease
·
Effectively
plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential
·
Make
more informed business decisions from insightful and in-depth analysis of drug
performance
·
Obtain
sales forecast for drugs from 2012-2022 in 5EU
Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=164947
.
For further information on “PharmaPoint: Prophylactic
Hepatitis B Virus Vaccines – 5EU Drug Forecast and Market Analysis to 2022”
report OR for any other business research / market intelligence need on the ‘Hepatitis-Drugs’
market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hepatitis-drugs
. ), contact sales@rnrmarketresearch.com
/ Call +1 888 391 5441.
